Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis


30 Sep 2019


Poster Display session 3



Tumour Site


Pierpaolo Correale


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


P. Correale1, N. Staropoli2, P. Pastina3, R. Giannicola1, C. Botta2, E. Francini4, L. Ridolfi5, E. Mini6, D. Ciliberto2, R.M. Agostino1, A. Strangio1, D. Azzarello1, V. Nardone7, A. Falzea1, P. Tassone2, A. Giordano8, L. Pirtoli8, G. Francini4, P.S. Tagliaferri2

Author affiliations

  • 1 Medical Oncology Unit, "Bianchi-Melacrino-Morelli" Grand Metropolitan Hospital, 89125 - Reggio Calabria/IT
  • 2 Medical Oncology Unit, Departement of Experimental and Clinical Medicine, Magna Graecia University, 88100 - Catanzaro/IT
  • 3 Unità Di Radioterapia, Azienda Ospedaliera Universitaria Senese-Istituto Toscano Tumori, 53100 - Siena/IT
  • 4 Medical Oncology Unit, Siena University Hospital, 53100 - Siena/IT
  • 5 Immunotherapy, Cell Therapy and Biobank, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, 47014 - Meldola/IT
  • 6 Oncology, Azienda Ospedaliera Universitaria Careggi, 50134 - Firenze/IT
  • 7 Unit Of Radiation Oncology, Ospedale del Mare, 80147 - Napoli/IT
  • 8 Biology, College of Science and Technology, Temple University, 19122 - USA/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3808


Immune-checkpoint blockade has shown anti-tumor activity in MSI mCRC patients only, thus, the research of more efficacious immunological strategies for colon cancer treatment is still open. GOLFIG, is a safe and active chemo-immunotherapy regimen designed on the basis of preclinical immune-oncological findings and evaluated in two subsequent Phase II and III trials in mCRC patients (J Clin Oncol, 2005,23:8950; J Immunother, 2014;37:26). This regimen combines gemcitabine + FOLFOX poly-chemotherapy with salgramostim (GM-CSF) and low dose sc. aldesleukin, to improve both cross-priming and T-cell effector anti-tumor response. Here we report a fifteen-year retrospective analysis of all patients undergone this therapeutic approach.


This is a multi-institutional real-life study including one hundred-seventy-nine mCRC patients receiving GOLFIG regimen between October 2001 and November 2018 with a median follow up of 120 months. The treatment was administered to 62 patients (GOLFIG-2 trial, EUDRACT: 2005-003458-81) as a first-line and to 117 patients as second/third-line (49 enrolled in the GOLFIG-1 phase II trial and 68 as real life). Kaplan-Meier and Cox-regression were carried-out to relate their PFS and OS with sex, age, sidedness, RAS mutational status, previous treatment lines, baseline clinical parameters and treatment-related irAEs.


We recorded a PFS and OS of 15.3 (95%CI:10.4-20.2) and 24.6 (95%CI:19.07-30.14) months, respectively, with 10% of the patients surviving more than ten years. Patients’ outcome did not correlate with sex, sidedness and RAS. First line GOLFIG confirmed superiority over FOLFOX in term of PFS (HR = 0.58 p = 0.006) and OS (HR = 0.69, P = 0.06) (updated from GOLFIG-2 trial). Patients in first-line showed a longer PFS (HR = 0.69; p = 0.041) compared with the others, with no difference in OS. On the overall, a longer PFS and OS correlated with baseline neutrophil counts ≤ 4,500 cells/µl (HR:0.32; P = 0.003) and occurrence of irAEs (HR = 0.36; P = 0.0001) recorded in 24% of the cases.


These results confirm that the GOLFIG regimen is a reliable therapy for pretreated mCRC patients and offer the rationale to design combination trials with immune-checkpoint blockade.

Clinical trial identification

1) GOLFIG-2 phase III trial; EudraCT: 2005-003458-81 2) GOLFIG-1 phase II trial; EudraCT no available, start July 2001.

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Italian Ministry of Education and Research (MIUR) (2009EHW394). Private grant from the “Associazione Culturale Federico II,” and from the “Associazione Riuniti Calabria Oncologia (ARCO)”.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.